Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

Cited In for PubMed (Select 21925771)

1.

The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.

Cooper-Knock J, Kirby J, Highley R, Shaw PJ.

Neurotherapeutics. 2015 Apr;12(2):326-39. doi: 10.1007/s13311-015-0342-1.

2.

A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD.

Rollinson S, Bennion Callister J, Young K, Ryan SJ, Druyeh R, Rohrer JD, Snowden J, Richardson A, Jones M, Harris J, Davidson Y, Robinson A, Ealing J, Johnson JO, Traynor B, Mead S, Mann D, Pickering-Brown SM.

Neurobiol Aging. 2015 Mar;36(3):1601.e1-5. doi: 10.1016/j.neurobiolaging.2014.12.009. Epub 2014 Dec 12.

3.

Genome-wide association studies in neurology.

Tan MS, Jiang T, Tan L, Yu JT.

Ann Transl Med. 2014 Dec;2(12):124. doi: 10.3978/j.issn.2305-5839.2014.11.12. Review.

4.

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases.

Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, Plagnol V, Gibbs JR, Schulte C, Pankratz N, Sutherland M, Bertram L, Lill CM, DeStefano AL, Faroud T, Eriksson N, Tung JY, Edsall C, Nichols N, Brooks J, Arepalli S, Pliner H, Letson C, Heutink P, Martinez M, Gasser T, Traynor BJ, Wood N, Hardy J, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Disease meta-analysis consortium.

Neurobiol Aging. 2015 Mar;36(3):1605.e7-12. doi: 10.1016/j.neurobiolaging.2014.07.028. Epub 2014 Aug 4.

5.

The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism.

Schottlaender LV, Polke JM, Ling H, MacDoanld ND, Tucci A, Nanji T, Pittman A, de Silva R, Holton JL, Revesz T, Sweeney MG, Singleton AB, Lees AJ, Bhatia KP, Houlden H.

Neurobiol Aging. 2015 Feb;36(2):1221.e1-6. doi: 10.1016/j.neurobiolaging.2014.08.024. Epub 2014 Aug 27.

6.

Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion.

Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, Beck J, Preza E, Devoy A, Sidle K, Howard R, Malaspina A, Orrell RW, Clarke J, Lu CH, Mok K, Collins T, Shoaii M, Nanji T, Wray S, Adamson G, Pittman A, Renton AE, Traynor BJ, Sweeney MG, Revesz T, Houlden H, Mead S, Isaacs AM, Fisher EM.

Neurobiol Aging. 2015 Jan;36(1):546.e1-7. doi: 10.1016/j.neurobiolaging.2014.07.037. Epub 2014 Aug 1.

7.

Genetic architecture of ALS in Sardinia.

Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Parish LD, Occhineri P, Cau TB, Loi D, Ticca A, Traccis S, Manera U, Canosa A, Moglia C, Calvo A, Barberis M, Brunetti M, Pliner HA, Renton AE, Nalls MA, Traynor BJ, Restagno G, Chiò A; ITALSGEN and SARDINALS Consortia.

Neurobiol Aging. 2014 Dec;35(12):2882.e7-2882.e12. doi: 10.1016/j.neurobiolaging.2014.07.012. Epub 2014 Jul 18.

PMID:
25123918
8.

Searching for Grendel: origin and global spread of the C9ORF72 repeat expansion.

Pliner HA, Mann DM, Traynor BJ.

Acta Neuropathol. 2014 Mar;127(3):391-6. doi: 10.1007/s00401-014-1250-x. Epub 2014 Feb 5.

9.

The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.

Cooper-Knock J, Shaw PJ, Kirby J.

Acta Neuropathol. 2014 Mar;127(3):333-45. doi: 10.1007/s00401-014-1251-9. Epub 2014 Feb 4. Review.

10.

Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective.

Fernandes SA, Douglas AG, Varela MA, Wood MJ, Aoki Y.

J Nucleic Acids. 2013;2013:208245. doi: 10.1155/2013/208245. Epub 2013 Nov 17. Review.

11.

Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics.

Landqvist Waldö M, Gustafson L, Nilsson K, Traynor BJ, Renton AE, Englund E, Passant U.

Am J Neurodegener Dis. 2013 Nov 29;2(4):276-86. eCollection 2013.

12.

Clinical Characteristics of C9ORF72-Linked Frontotemporal Lobar Degeneration.

Kaivorinne AL, Bode MK, Paavola L, Tuominen H, Kallio M, Renton AE, Traynor BJ, Moilanen V, Remes AM.

Dement Geriatr Cogn Dis Extra. 2013 Aug 20;3(1):251-62. doi: 10.1159/000351859. eCollection 2013.

13.

A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, Goh A, McCusker E, Williams JK.

Prog Neurobiol. 2013 Nov;110:2-28. doi: 10.1016/j.pneurobio.2013.08.003. Epub 2013 Sep 11. Review.

14.

Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.

Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA.

Neuroepidemiology. 2013;41(2):118-30. doi: 10.1159/000351153. Epub 2013 Jul 11. Review.

15.

C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease.

Nuytemans K, Bademci G, Kohli MM, Beecham GW, Wang L, Young JI, Nahab F, Martin ER, Gilbert JR, Benatar M, Haines JL, Scott WK, Züchner S, Pericak-Vance MA, Vance JM.

Ann Hum Genet. 2013 Sep;77(5):351-63. doi: 10.1111/ahg.12033. Epub 2013 Jul 12.

16.

Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis.

Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred P, Cruchaga C, Baughn M, Libby RT, Pestronk A, Goate A, Ravits J, Baloh RH.

Neurobiol Aging. 2013 Sep;34(9):2234.e13-9. doi: 10.1016/j.neurobiolaging.2013.03.006. Epub 2013 Apr 16.

17.

C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease.

Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, Carrell D, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, Mayeux R, Chakraverty S, Goate AM, Cruchaga C; NIA-LOAD/NCRAD Family Study Consortium.

JAMA Neurol. 2013 Jun;70(6):736-41. doi: 10.1001/2013.jamaneurol.537.

18.

C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients.

Dobson-Stone C, Hallupp M, Loy CT, Thompson EM, Haan E, Sue CM, Panegyres PK, Razquin C, Seijo-Martínez M, Rene R, Gascon J, Campdelacreu J, Schmoll B, Volk AE, Brooks WS, Schofield PR, Pastor P, Kwok JB.

PLoS One. 2013;8(2):e56899. doi: 10.1371/journal.pone.0056899. Epub 2013 Feb 20.

19.

Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.

Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, Orrell RW, Malaspina A, Rowe J, Brown J, Hodges J, Sidle K, Polke JM, Houlden H, Schott JM, Fox NC, Rossor MN, Tabrizi SJ, Isaacs AM, Hardy J, Warren JD, Collinge J, Mead S.

Am J Hum Genet. 2013 Mar 7;92(3):345-53. doi: 10.1016/j.ajhg.2013.01.011. Epub 2013 Feb 21.

20.

Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.

Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, Wood EM, Shaw LM, Woo JH, Cook PA, Wolk DA, Arnold SE, Van Deerlin VM, McCluskey LF, Elman L, Lee VM, Trojanowski JQ, Grossman M.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):163-9. doi: 10.1136/jnnp-2012-303507. Epub 2012 Oct 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk